The effect of menopausal hormone therapy on the risk of melanoma and keratinocyte skin cancer: A systematic review and meta-analysis of observational studies

The re-analysis of Women's Health Initiative and the publication of data emerging from recent clinical trials data have restored the initial decline in the use of menopausal hormone therapy (MHT), due to adverse events, such as stroke and pulmonary embolism [1,2]. Nowadays, an increasing number of women treat their menopausal symptoms with hormonal therapies, which exhibit a better safety profile. However, the association of MHT with cancer development remains a potent drawback, with breast and endometrial cancer being the most frequently reported neoplasms [3,4].

Source: Maturitas - November 4, 2022 Category: Primary Care Authors: Konstantinos Lallas, Panagiotis Anagnostis, Patroklos Theocharis, Eirini Boureka, Athanasios Kyrgidis, Eleftherios Klonos, Georgios Papazisis, Zoe Apalla, Aimilios Lallas, Efstratios Vakirlis Tags: Review article Source Type: research